Peptide Reports

CJC 1295 no DAC Peptide Report

Peptide Report

CJC 1295 no DAC Peptide Report

Catalog report for CJC 1295 no DAC, generated from Peptide Stacks product data and linked to the matching PeptideReports protocol page when available.

All peptide reportsProtocol library
Current Price$40.00 CAD
ProtocolCJC-1295 no DAC protocol
Catalog SourceBuy Product

Available Options

  • 10 MG

Common Uses

People commonly discuss CJC-1295 no DAC for growth-hormone pulse support, recovery, sleep quality, and body-composition goals where a shorter-acting option is preferred.

How It Works

CJC-1295 no DAC is a shorter-acting GHRH analog. It works by binding growth-hormone-releasing hormone receptors at the pituitary, encouraging pulsatile growth-hormone release without the albumin-binding extension used in DAC versions.

Storage

Powder form: In lyophilized powder form, CJC 1295 no DAC is generally kept sealed, dry, protected from direct light, and refrigerated unless the product label or certificate of analysis gives different handling instructions. Avoid leaving vials in hot rooms, vehicles, direct sunlight, or other temperature swings, because moisture, heat, and light are the main storage conditions people try to control before reconstitution.

Reconstituted: After reconstitution, CJC 1295 no DAC should generally be treated as more sensitive: keep it refrigerated, minimize unnecessary handling, avoid shaking, and use clean handling practices each time the vial is accessed. Follow the product label, protocol page, and any pharmacy or lab guidance for beyond-use timing; if the solution changes color, becomes cloudy, develops particles, or the vial integrity is questionable, it should not be used.

Protocol

The full CJC-1295 no DAC protocol is included below. The standalone protocol page remains available if you want to open it separately.

Open Standalone Protocol

Scope

Preparation examples, syringe conversion, community-reported patterns and important limitations.

Available strengths: 10 MG

Preparation Examples

These are calculation examples only. The concentration assumptions below are explicit so syringe units are never separated from vial strength and diluent volume.

Setup Diluent Concentration Unit conversion
10 MG vial – 2 mL example Add 2 mL bacteriostatic water 5 mg/mL Each U-100 unit = 50 mcg
10 MG vial – 1 mL example Add 1 mL bacteriostatic water 10 mg/mL Each U-100 unit = 100 mcg

Syringe Conversion

Reported amount 10 MG setup 10 MG setup
100 mcg 2 units 1 units
200 mcg 4 units 2 units
300 mcg 6 units 3 units
500 mcg 10 units 5 units

Always recalculate from the actual vial strength and diluent volume. A U-100 unit is 0.01 mL; it is not a dose by itself.

Community-Reported Patterns

Recurring report Frequency seen Context in reports
100 mcg Once daily Lower-start reports
100-200 mcg One to three times daily Most recurring range
300 mcg Once or twice daily Higher experimental use

Observations

  • Community discussions most often centered on sleep quality, recovery and growth-hormone pulse research.
  • The amount, frequency, route and cycle length varied substantially between reports.
  • Reported outcomes were commonly confounded by diet, training, other products or existing treatment.

Caveats

  • Confirm the product is no DAC. Community schedules for DAC and no-DAC forms are not interchangeable.
  • Community reports are uncontrolled anecdotes and do not establish an appropriate dose, safety, product identity, purity or efficacy.

Sources

  1. Community search: CJC-1295 no DAC
  2. PubMed literature search: CJC-1295 no DAC